Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: A randomized, open-label, multicentre, 12-week phase III study-Reference-Cited by-同舟云学术

Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: A randomized, open-label, multicentre, 12-week phase III study

Published:2017-03-01 Issue:4 Volume:22 Page:293-300
ISSN:1320-5358
Container-title:Nephrology
language:en
Short-container-title:Nephrology

Author:

Koiwa Fumihiko¹,Yokoyama Keitaro²,Fukagawa Masafumi³,Terao Akira⁴,Akizawa Tadao⁵

Affiliation:

1. Division of Nephrology, Department of Medicine; Showa University Fujigaoka Hospital; Yokohama Japan

2. Division of Nephrology and Hypertension, Department of Internal Medicine; The Jikei University School of Medicine; Tokyo Japan

3. Division of Nephrology, Endocrinology and Metabolism; Tokai University School of Medicine; Isehara Japan

4. Biostatistics, Faculty of Pharmaceutical Sciences; Josai University; Sakado Japan

5. Division of Nephrology, Department of Medicine; Showa University School of Medicine; Tokyo Japan

Funder

ClinicalTrials.gov

Publisher

Wiley

Subject

Nephrology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/nep.12891/fullpdf

Reference19 articles.

1. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis;Block;J. Am. Soc. Nephrol.,2004

2. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients;Kalantar-Zadeh;Kidney Int.,2006

3. Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder;Fukagawa;Ther. Apher. Dial.,2013

4. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease;National Kidney Foundation;Am. J. Kidney Dis.,2003

5. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients;Bleyer;Am. J. Kidney Dis.,1999

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of iron on cardiovascular, kidney and safety outcomes in patients with chronic kidney disease: a systematic review and meta-analysis;2024-03-28

2. Tolerability, safety, and efficacy of a novel phosphate binder VS-505 (AP301): a Phase 2 dose-escalation and dose-ranging study in patients undergoing maintenance hemodialysis;Nephrology Dialysis Transplantation;2024-03-07

3. Association of Sevelamer Initiation with Gastrointestinal Bleeding Hospitalization in Individuals Requiring Hemodialysis;American Journal of Nephrology;2024

4. Efficacy and Safety of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in Chinese Dialysis Patients with Hyperphosphataemia: A Randomised, Open-Label, Multicentre, 12-Week Phase III Study;Nephron;2023-07-20

5. Safety and effectiveness of sucroferric oxyhydroxide in Spanish patients on dialysis: sub-analysis of the VERIFIE study;Nefrología (English Edition);2022-09